September 24-26, 2024 | Boston, MA
www.mashdrugdevelopmentsummit.com

REGISTER BY FRIDAY, JUNE 14 AND SAVE UP TO $1,100

WELCOME
EXPERT SPEAKERS
AGENDA
PARTNER WITH US
REGISTER YOUR PLACE

8th Annual
MASH Drug Development Summit
Driving MASH Drug Development & Navigating the Evolving Metabolic & Obesity Landscape

Assessing MASH Patient Populations & Evaluating Clinical Data to Accelerate Efficacious MASH Therapeutics Through the Clinic to Patients

Expert Speakers Include:

Gerald Horan
Senior Director
Bristol Myer Squibb

Kristin Fiorino
Medical Director
AstraZeneca

Stephanie Watkins
Senior Director
Gilead



Emma Henriksson
Liver Disease
Research Manager
Novo Nordisk

Pitchumani Sivakumar
Director
Pfizer

Rebecca Taub
Chief Medical Officer
Madrigal

Proud to Partner With:

Antaros Medical · Perspectum · Summit Clinical Research · ALMAC · KBI BIOPHARMA · Physiogenex · gubra

+1 617 455 4188 | info@hansonwade.com
www.mashdrugdevelopmentsummit.com | Obesity, NASH & CVRM Drug Development

hansonwade

The Industry's Definitive Event for MASH Drug Development

120+
Experts Across the Community

40+
Thought Leading Speakers

8+
Hours of Face-to-Face Networking

There's no doubt the MASH landscape has been shaken up. Madrigal's Rezdiffra has secured FDA approval as the very first MASH therapeutic, plus a wave of new promising therapeutics in phase 1, 2 and 3 clinical trials are on the horizon from **Boehringer Ingelheim, AstraZeneca, Amgen, Akero, 89Bio**, and more.

The **8th MASH Drug Development Summit** *(formally the NASH Summit)* unites 120+ industry leaders to celebrate progress and address the most pressing challenges in MASH and metabolic diseases. From optimizing clinical trial design, overcoming regulatory challenges, combatting fibrosis, navigating GLP-1 usage, optimizing RWE integration and achieving accurate non-invasive biomarkers. Moreover, with FGF21s, THR-β agonists, GLP-1 agonists, FXR and PPAR agonists therapeutic modalities driving forward the MASH therapeutic pipelines, this is your opportunity to access cutting-edge R&D insights that can supercharge your end-to-end pipeline development strategy.

Built by MASH experts for MASH leaders, the **8th MASH Drug Development Summit** is your team's opportunity to harness competitive intelligence from data driven industry presentations across 3-days of cutting-edge content, with the power to propel your MASH therapeutic pipeline.

Here is what Your Industry Colleagues Have to Say

"Multidisciplinary meetings such as this are important to bring together groups to find the optimal ways to treat a complex disease such as MASH"

Chief Scientific Officer, Cirius Therapeutics

"The MASH Summit agenda captures the urgent issues for MASH drug development. I'm happy to present as a speaker as well as to hear all the exciting update and future perspectives"

Director, AstraZeneca

Top 5 Unmissable Program Insights

Delve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with **Novo Nordisk**, **BMS**, **Pfizer** and **AstraZeneca.**

Accelerate Accelerate your clinical trial by optimizing MASH and fibrosis targetted endpoints and creating operational synergies between cirrhotic and non-cirrohtic trials with **AstraZeneca** and **89Bio**.

Examine how GLP-1s can be leveraged in MASH to combat the disease drivers with **Gilead**, **Altimmune** and **Seal Rock Therapeutics.**

Explore how the regulatory field is shifting and learn how to navigate regulatory approval with **Madrigal** and **AstraZeneca.**

Leverage AI techniques and real world evidence to integrate data, harmonize predictions and identify future trends for MASH with **Merck** and **AstraZeneca.**

What's New for 2024?

8th Annual MASH Drug Development Summit
September 24-26, 2024 | Boston, MA

Dedicated Content Stream for All Your Teams: Built to accommodate a rapidly expanding audience spanning the end to end journey or preclinical, translational, clinical and regulatory.

25+ Brand New Speakers: Broaden your network of industry peers working across metabolic and fibrotic disease with fresh faces bringing novel insights from the likes of AstaZeneca, Pfizer, Gilead and Regeneron.

Refreshed Content for the Whole Team

Pre-Conference Workshop Day		Conference Day 1		Conference Day 1	
Track 1: Preclinical & Translational	Track 2: Clinical and Regulatory	Exploxing the MASH State of Play		RWE & Non Invasive Biomarker Developments	
Morning Break		Track 1: Preclinical & Translational	Track 2: Clinical and Regulatory	Track 1: Preclinical & Translational	Track 2: Clinical and Regulatory
Track 1: Preclinical & Translational	Track 2: Clinical and Regulatory	Lunch & Networking		Lunch & Networking	
Lunch & Networking		Track 1: Preclinical & Translational	Track 2: Clinical and Regulatory	Track 1: Preclinical & Translational	Track 2: Clinical and Regulatory
Track 1: Preclinical & Translational	Track 2: Clinical and Regulatory	Afternoon Break		Afternoon Break	
End of Workshop Day		The Journey Toward the Next Wave of Approvals		What's Next for MASH Drug Development?	

2024's Drug Development Landscape

*This figure is provided for informational purposes only and is not designed to be factually accurate. Companies and candidates operating in MASH may not be included. Users are advised to verify information independently before making decisions based on this data.

Your 40+ Expert Speakers

8th Annual MASH Drug Development Summit
September 24-26, 2024 | Boston, MA

Adam Bell
Vice President
Neuraly

Bonnie Fendrock
Chief Executive Officer
Cyta Therapeutics

Charlotte Scott
Professor
Ghent University

Cynthia Arbeeny
Chief Scientific Officer
Mitotherapeutix

David Brenner
Chief Executive Officer
Sanford Burnham Prebys

David Lloyd
Vice President
Insitro

Emma Henriksson
Manager
Novo Nordisk

Ezra Lowe
Vice President
Galectin Therapeutics

Gerald Horan
Senior Director
Bristol Myers Squibb

Hank Mansbach
Chief Medical Officer
89 Bio

Jay Kim
Chief Executive Officer
Therasid Bioscience

Jeff McIntyre
Vice President
Global Liver Institute

Jerry Colca
Chief Scientific Officer
Cirius Therapeutics

Jingyu (Julia) Luan
Senior Director
AstraZeneca

Kai-Min Chu
Chief Executive Officer
Sinew Pharma

Kathleen Elias
Vice President
Seal Rock Therapeutics

Kristin Fiorino
Medical Director
AstraZeneca

Manu Chakravarthy
Chief Medical Officer
Carmot

Maria Trujillo
Senior Principle Scientist
Merck

Matthew Bryant
Vice President
Boston Pharmaceuticals

Meena Bansal
Professor
Mount Sinai

Michael Cooreman
Chief Medical Officer
Inventiva

Miriam Kidrom
Chief Scientific Officer
Oramed

Pitchumani Sivakumar
Director
Pfizer

Your 40+ Expert Speakers

8th Annual MASH Drug Development Summit
September 24-26, 2024 | Boston, MA

Rebecca Taub
Chief Medical Officer
Madrigal

Reshma Shringapure
Vice President
Akero

Rosemarie Sellati
Director
Regeneron

Sarah Will
Director
AstraZeneca

Scott Harris
Chief Medical Officer
Altimmune

Stephanie Watkins
Senior Director
Gilead

Tatiana Kisseleva
Associate Professor
University of California

Thomas Fabre
Senior Principle Scientist
Pfizer

Yao-Yao Zhu,
Director
AstraZeneca

Sophie Jeannin
Chief Medical Officer
Summit Clinical Research

Speaker to be confirmed
Almac

Speaker to be confirmed
KBI

Speaker to be confirmed
Physiogenex

Speaker to be confirmed
Perspectum

> "The presentation topics were phenomenal. In addition, the size of the meeting allowed for 1:1 discussions with many of the attendees"
>
> **Senior Director, Antaros Medical**

> "Excellent speakers, good topics on agenda and networking opportunities to meet likeminded groups"
>
> **ARIA Pharmaceuticals**

Pre-Conference Workshop Day
Tuesday, September 24, 2024

8th Annual MASH Drug Development Summit
September 24-26, 2024 | Boston, MA

8.00 Check In & Coffee

Preclinical & Translational Track

9.00 Workshop A: Maximizing Translatability of Models: A Comprehensive Comparison of Existing Models

- From GAN2 models, to IPSC models, to organ and chip, precision liver slices, and organoids models, which model is optimal? This workshop will be a deep dive comparison i*n vitro* and *in vivo* model complexity and translatability.
- Discuss developments which impact the suitability of different models for testing targets.
- Comparing robustness, scalability, and reproducibility between model types.

Sarah Wills, Director, **AstraZeneca** NEW DATA

David Brenner, Chief Executive Officer, **Sanford Burnham Prebys**

Clinical & Regulatory Track

9.00 Workshop B: Regulating Insulin Sensitivity in MASH

- Insulin resistance is understood to be a central pathology driving the progression of MASH. NEW DATA
- There are new understandings of the biological mechanisms of action behind the pathways driving pathology in the liver and other organs.
- We will discuss ways of moving this field forward.

Jerry Colca, Chief Scientific Officer, **Cirius**

Manu Chakravarthy, Chief Scientific Officer, **Carmot**

11.00 Morning Break

11.30 Workshop C: Delving into *In Vitro* and *In Vivo* Approaches to Improve Fibrosis Replication

- *In vitro* and *in vivo* approaches to model fibrosis are currently a key challenge. There is a need to evaluate and incorporate all aspects of MASH into one system. With current approaches being used to induce fibrosis being highly irrelevant to human systems, this workshop will explore approaches to improve fibrosis modelling. Exploring how to integrate metabolic, arterial, and sympathetic health into a fibrosis system.

Emma Henrickson, Liver Disease Research Manager, **Novo Nordisk**

11.30 Workshop D: Exploring Non-Invasive Tests & Biomarkers for MASH in Action

- Delving into promising results for SNP-6 Series in treating MASH with multi-functional effects and a POC Quantitative Non-Invasive Test for MASH: Insights from animal and clinical trials. Showing clinically significant improvements in biomarkers of liver injury, inflammation, and fibrosis in a Phase 2 study in patients with MASH. Also exploring a case study of this in a phase 2 oral insulin versus placebo study.

Kai-Min Chu, Chief Executive Officer, **Sinew**

Miriam Kidrom, Chief Scientific Officer, **Oramed**

1.30 Lunch Break

2.30 Workshop E: Illuminating Novel Target Identification for MASH

- Explore the latest advancements in identifying genetic targets and protein-based therapies for MASH. Devling into the power of machine learning and data at scale to decode the complexities of MASH. Aswell as the inhibition of the Galectin-3 protein as a novel target for the treatment of MASH.

David Lloyd, Vice President, **Insitro**

Ezra Lowe, Vice President, **Galectin Therapeutics**

2.30 Workshop F: Utilizing Early Phase Integrated Evidence Planning (IEP) to Streamline Non-Interventional Research Supporting MASH Therapeutic Development

Discuss process, value, and lessons learned around the development of an early phase integrated evidence plan supporting drug development for fibrotic MASH.

- Differences between early and late stage IEP
- Getting buy in with cross functional stakeholders
- Why do an early phase IEP in this space
- Running the IEP execution team
- Lessons learned and impact for the program

Stephanie Watkins, Senior Director, **Gilead**

4.30 End of Workshop Day

Conference Day One
Wednesday, September 25, 2024

7.30 **Check-In & Light Breakfast**

8.25 **Chair's Opening Remarks**

Navigating the Recently Reshaped MASH Landscape to Maximize Therapeutic Success

8.30 **Panel Discussion | Exploring the State of Play with Rezdiffra's Approval**

- Discussing the impact of Rezdiffra on the therapeutic treatment of MASH
- Assessing how clinical trials and other drug classes are affected
- How will the standard of care be impacted?


Rebecca Taub
Chief Medical Officer
Madrigal


Kristin Fiorino
Medical Director
AstraZeneca


Adam Bell
Vice President
Neuraly


Rebecca Taub
Chief Medical Officer
Madrigal

9.00 **Unlocking Madrigal's Experience with Regulatory Challenges**

- Leveraging learnings from Rezdiffra's recent approval
- Exploring how no biopsy requirement was achieved
- Unearthing how their clinical trial and endpoints were defined


Kristin Fiorino
Medical Director
AstraZeneca

9.30 **Establishing Robust Clinical Trial Design to Overcome Past Failings**

- Reducing screen failure rates through effective design
- Optimizing cirrhosis, MASH and fibrosis targeting in trials
- Regulatory pathways for cirrhosis
- Targeted endpoints for MASH and cirrhosis

10.00 **Speed Networking**
A prime chance to make the most of the in-person networking with a niche community of MASH professionals working in space. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.

10.45 **Morning Break**

Track 1: Preclinical & Translational

Navigating the Fibrotic & Inflammatory Components of MASH to Achieve a Holistic Therapeutic

11.00 **Session reserved for Physiogenex**

Physiogenex
THE METABOLIC DISEASES EXPERTS

Track 2: Clinical & Regulatory


Chair: Sophie Jeannin, Chief Medical Officer, **Summit Clinical Research**

Overcoming Screen Failures by Advancing MASH Trial Formatting

11.00 **Session Reserved for Summit Clinical Research**

Summit Clinical Research

Conference Day One
Wednesday, September 25, 2024

11.10 Making "Sense of the Mess": How to Define and Drug Functional Subsets of Macrophage Contributing to Fibrosis Progression? NEW DATA

- With substantial advancements in the metabolic treatment of MASH how can fibrosis and inflammation be effectively combated?
- Overview of preclinical antifibrotic developments
- Delving into mechanistic insights and targeting of myosatellites

Thomas Fabre, Senior Principle Scientist, **Pfizer**

11.10 Navigating the Sub Stratification of Cirrhotic Patients to Optimize in Clinical Trial Design

- Factoring the continuum state of cirrhosis into MASH clinical trial design
- Which pathways to target at different points of the continuum

Meena Bansal, Professor, **Mount Sinai**

11.40 Session Reserved for KBI

KBI BIOPHARMA

11.40 Session Reserved for Almac

ALMAC
Partnering to Advance Human Health

11.50 Understanding the Role of Macrophages in the Progression of MASLD NEW DATA

- Exploring the subtypes of macrophages as MASLD progresses
- Investigating the functional relevance of the different subsets at different disease settings

Charlotte Scott, Professor, **Ghent University**

11.50 Conducting Cirrhotic & Non-Cirrhotic Trials in Parallel a Case Study

- Exploring approaches to operational synergies
- Detailing criteria for site selection
- Achieving regulatory synergies

Hank Mansbach, Chief Executive Officer, **89Bios**

12.20 Lunch

Track 1: Preclinical & Translational

Biomarkers, TBF- B Manipulation & Thyromimetic Drugs to Catalyze Preclinical Success

1.20 Deep Diving into Biomarker Results From a Phase 2 Study of the CC-90001 JNK Inhibitor in NASH with Advanced Fibrosis NEW DATA

- Exploring how biomarkers can inform on mechanisms of fibrosis
- Treatment of F3 NASH Subjects with the CC-90001 JNK inhibitor associated with dose-dependent reductions in multiple biomarkers of fibrosis, including ELF and PRO-C3
- Dose-dependent reductions in imaging MRE score were consistent with serum fibrosis biomarker results
- Effects of CC-90001 appeared to be mostly anti-fibrotic with little impact on imaging or biopsy measures of steatosis

Gerald Horan, Senior Director, **BMS**

Track 2: Clinical & Regulatory

Leveraging GLP-1 Class for MASH Drug Development

1.20 Delving into the Application of the Obesity Drug Revolution for MASH:DD01 a Unique Dual Agonist that Rapidly Reduces Liver Fat' after the word MASH NEW DATA

- DD01 is well tolerated at doses that rapidly reduce hepatic steatosis and improve glucose tolerance in obese diabetics with diabetes and MASLD
- Mechanistic studies in animals reveal DD01 is more effective than calorie restriction or treatment with a GLP-1 in reducing liver fat and reveal concurrent improvements in clinical markers of MASH resolution that are not matched by equivalent doses of semaglutide
- The unique therapeutic profile of DD01, a pegylated GLP1/Glucagon receptor agonist, show it provides rapid reductions in hepatic steatosis that are attributable to glucagon and can be uncoupled from the more gradual effects of calorie restriction and weight loss

Adam Bell, Vice President, **Neuraly**

Conference Day One
Wednesday, September 25, 2024

1.50 Tackling Fibrosis Through TGF-β Manipulation NEW DATA

- Wound healing and fibrosis: Two sides of the coin
- Unearth molecular mechanism of TGF-β activation
- Dissect the cellular targets and downstream effects of TGF-β signaling
- Unlock TGF-β signaling dynamics and potential therapeutic target

Jay Kim, Chief Executive Officer, **Therasid Bioscience**

1.50 Investigating Combinational Approaches to Elevate GLP-1 Therapies: Role of 2nd generation ASK1 inhibitor SRT-015 treatment for MASH fibrosis NEW DATA

- SRT-015 is an oral compound with direct pleotropic effects on the liver including fibrotic, inflammatory and apoptosis inhibition for possible use in all MASH fibrosis stages
- Combination therapy with GLP-1s and other metabolic agents
- In a phase 1 clinical trial, SRT-015 demonstrated pharmacokinetics that enables daily dosing with a favorable safety profile

Kathleen Elias, Co-founder, **Seal Rock Therapeutics**

2.20 Exploring Approaches to Deliver Thyromimetic Drugs for Obesity

- Weight loss with TRbeta agonist in DIO model
- Lowering of cardiovascular biomarkers
- Potential alternatives or combination approach with GLP1s

Bonnie Fendrock, Chief Executive Officer, **Cyta Therapeutics**

2.20 Unlocking Glucagon Biology to Overcome Fibrosis in MASH

- Understanding the therapeutic benefit of glucagon-based agents on serum and hepatic lipids
- Navigating Pemvitutide Phase 2b trial data
- Analyzing the effect on inflammation, LDL cholesterol and body composition

Scott Harris, Chief Medical Officer, **Altimmune**

2.50 Afternoon Break & Poster Session

Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversions and relationship building. Explore a range of exciting poster presentations of the latest MASH strategies and showcase your own innovations in MASH drug development. Don't miss out on the chance to connect, learn, and present.

Showcasing Future Consideration with Clinical Guidelines, Imaging & Surrogate Endpoints

3.30 Panel | Translating GLP-1s, Rezmiteron, FGF21 Therapies into Clinical Practice Guidelines in a Rapidly Changing Landscape

- Assessing how current therapies fit into the standard of care
- Navigating the future of combination therapies to optimize treatment
- Evaluating how this will play out in the real world with access, non-responders, standard of care and the shift to primary care providers

Reshma Shringarpure
Vice President
Akero

Matt Bryant
Vice President
Boston Pharmaceuticals

Kathleen Elias
Co-Founder
Seal Rock Therapeutics

Antaros Medical

4.00 Session Reserved

4.30 Chair's Closing Remarks

Conference Day Two
Thursday, September 26, 2024

7.30 Check-In

8.25 Chair's Opening Remarks

Jingyu (Julia) Luan
Executive Director
AstraZeneca

8.30 **Utilizing RWD/RWE to Improve MASH Drug Development Efficiency**

- Detailing the RWD/RWE regulatory landacape including FDA, EMA, PMDA and CDE
- Navigating global regulatory harmonization and convergence
- Utilizing case studies to predict future trends

Perspectum

9.00 Session Reserved

Pitchumani Sivakumar
Director Translational Medicine
Pfizer

9.30 NEW DATA **Exploring Biomarker Developments for Assessing Liver Fibrosis**

- Overcoming inherent limitations of liver biopsy and histological analysis through non-invasive tools
- Assessing potential of protein localization
- Exploring Visium Spatial and Xenium

10.00 Morning Break & Networking

Track 1: Preclinical & Translational

Navigating the Heterogeneity of MASH to Optimize Preclinical Success

10.45 **Elucidating the Potential of siRNA Approaches for MASH** NEW DATA

- siRNA therapies can modulate targets that were previously considered un-druggable by conventional small molecule or large molecule approaches
- A GalNAc-SiRNA therapeutic approach is a novel modality to specifically target a single gene in the liver without impact on non-hepatic tissues, leading to a good safety profile

Cynthia Arbeeny, Chief Scientific Officer, **Mitotherapeutix**

Track 2: Clinical & Regulatory

Utilizing Machine Learning & PPARs to Accelerate MASH Development

10.45 **Leveraging Quantitative Tools to Integrate Preclinical and Clinical Data to Advance MASH Drug Development** NEW DATA

- Integrating preclinical and clinical data via mathematical modeling predicts pharmcoldynamic effects on MASH biomarkers
- Mathematical models also characterize the relationship between MASH biomarkers and histological endpoints
- AI/ML techniques aiding participant selection and test model predictions to reduce screen failures

Maria Trujillo, Senior Director, **Merck**

Conference Day Two
Thursday, September 26, 2024

11.15 The Potential of Pan-PPAR Agonist Therapy to Address Inflammation and Fibrosis in Patients with MASH – a Path to a Holistic Approach

- Delving into the anti-fibrotic and anti-inflammatory impacts
- Assessing developments from Phase 3 trials

Michael P Cooreman, Chief Medical Officer, **Inventiva**

11.45 Lunch

12.45 Delving into Portal Fibroblast Ablation to Treat Cholestatic Fibrosis NEW DATA

- Activated Portal Fibroblasts (aPFs) and Hepatic Stellate Cells (aHSCs) contribute to populations of myofibroblasts in response to cholestatic liver fibrosis. Ablation of myofibroblasts with cell-specific immunotoxins or CART cells has been suggested as a potential immunotherapy of liver fibrosis
- Ablation of aPFs suppresses cholestatic liver fibrosis without causing mortality or distress in mice and can be used for treatment of cholestatic liver fibrosis
- Ablation of HSCs suppresses liver fibrosis but affects hepatocyte proliferation causing a defect in liver regeneration. Total ablation of HSC population cannot be used for anti-fibrotic therapy

Tatiana Kisseleva, Associate Professor, **University of California**

12.45 Exploring the Need for Regulatory Guidance for Decompensated MASH

- Analysing the need for guidelines for this critical population
- Considering necessary updates to account for differences in endpoints
- Guidance on patient selection and risk stratification

Yao-Yao Zhu, Regulatory Affairs Director, **AstraZeneca**

1.15 Roundtable | Navigating MASH Model Development

A practical and highly interactive breakout roundtable session where attendees can crowd-source and share opinions around assigned topic areas:

- How can model translatability be maximized?
- How to achieve fibrotic models in conjunction with established metabolic models

1.15 Roundtable | Optimizing MASH Drug Development

A practical and highly interactive breakout roundtable session where attendees can crowd-source and share opinions around assigned topic areas:

- Exploring key learnings and takeaways from regulatory bodies to inform future direction
- Exporting learnings from past clinical trials to optimize trial design and patient engagement

1.45 Afternoon Break

Showcasing Antifibrotic Progress, Past Learnings & Innovations to Supercharge MASH Drug Development

Reshma Shringarpure
Vice President
Akero

2.15 Spotlighting Clinical Data Supporting Anti-Fibrotic Mechanisms of EFX

- Detailing direct and indirect antifibrotic activity of EFX shown clinically
- Improving insulin sensitivity and restoring lipoprotein profile to restore metabolic health and achieve sustained responses
- Dissecting the implications of these findings on long term clinical outcomes

Rosemarie Sellati
Director
Regeneron

2.45 Harmonizing Patient Engagement & Patient Centered Clinical Trials

- Evaluating efforts to drive patient focused drug development
- Promoting diversity in MASH trials to increase access and representation
- Exploring the impact of recent approvals on the patient journey

Conference Day Two
Thursday, September 26, 2024

Jeff McIntyre
Vice President
Global Liver Institute

3.15 Detailing the Best Practises for Patient Engagement

- Utilizing case studies from a MASH power council
- Exemplifying best code of practise
- Implementing strategies to enhance patient-focuse drug development

3.45 Panel Discussion | What's Next for MASH Drug Development: Deep Diving into Innovations in the Field

- What are the future directions of MASH drug development?
- From GLP agonists, RNA therapies, AAV and SNPs which of these therapies hold the most promise
- Which pipelines should be prioritized?

Michael P Cooreman
Chief Medical Officer
Inventiva

Pitchumani Sivakumar
Director Translational Medicine
Pfizer

Cynthia Arbeeny
Chief Scientific Officer
Mitotherapeutix

4.15 Chair's Closing Remarks

"The scientific sessions were very relevant to my work, and many of the presentations were excellent — I learned more than I expected to"

Vice President, Boston Pharmaceuticals

"It is my great honor to be able to share our research and development achievements at this prestigious conference and to exchange ideas with top researchers from around the world."

Chief Executive Officer, Sinew Pharma

Take the Spotlight: Partner With Us

8th Annual MASH Drug Development Summit
September 24-26, 2024 | Boston, MA

The first MASH drug approval and the surge of investment in the space are propelling the next wave of efficacious MASH therapeutics from the clinic to patients. The **8th MASH Drug Development Summit** unites pioneering organizations dedicated to expediting therapeutic development for MASH. Covering a full spectrum from preclinical and translational to clinical and regulatory, this Summit offers an unparalleled opportunity to forge new and nurture existing relationships with biopharma that are activity seeking to streamline development.

How the 8th MASH Drug Development Summit Can Propel Your Success

Showcase Your Innovative Solutions

Engage with metabolic scientists spanning discovery, translational, clinical and regulatory expertise who are actively seeking high level support.

Enhance Business Connections

Secure valuable facetime with key metabolic and fibrotic decision-makers at *the* definitive industry meeting.

Thought Leadership

Stand out from your competitors in this rapidly evolving field by demonstrating to prospective clients how your MASH services and technologies can optimize their therapeutic development.

Elevate Brand Visibility

Increase you market share and grow awareness among hepatic experts through pre-conference and onsite advertising.

SENIORITY OF ATTENDEES*



- Chief – 24%
- President – 14%
- Director – 28%
- Manager – 12%
- Scientist – 9%
- Other – 13%

TYPES OF COMPANIES ATTENDING*



- Drug Developer and Healthcare Providers
- Service Provider
- Other

Statistics Taken from 7th NASH & Obesity Drug Development Summit

GET INVOLVED

Ellie Bilko
Senior Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Event Partners

Expertise Partner - Antaros Medical

Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decisionmaking at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.

www.antarosmedical.com

Expertise Partner - Perspectum

Perspectum is an innovative company pushing the frontier of personalized medicine through our advanced non-invasive imaging portfolio. Working across the obesity, MASH and metabolic disease space, our best-in-class precision health technology provides sponsors with tangible insights into the mechanisms and benefits of their treatments. Working across the entire development pipeline, we support sponsors to differentiate their treatments by allowing them to see and quantify more than ever before.

www.perspectum.com

Hosting Partner - Summit Clinical Research

Summit Clinical Research is an Integrated Research Organization which brings together experienced research sites with proven success in the Metabolic Dysfunction-associated Steatohepatitis (MASH) research space. Our mission is to execute comprehensive site recruitment and engagement strategy to achieve the target patient enrollment goal efficiently and cost-effectively within the projected timelines. We believe patients who participate in clinical trials are partners in their own healthcare. This philosophy is shared by our network of experienced MASH research sites.

www.summitclinicalreseach.com

Innovation Partner - Almac

Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle. We are trusted experts in R&D, diagnostic services, API manufacture, formulation development, clinical trial supply services and technologies through to commercial-scale manufacture and distribution.

www.almacgroup.com

GET INVOLVED

Ellie Bilko
Senior Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Event Partners

Innovation Partner - KBI

As the icon of next-generation CDMOs, KBI Biopharma is driving breakthroughs in biopharmaceutical development and manufacturing that positively impact the lives of patients worldwide.

www.kbibiopharma.com

Innovation Partner - Physiogenex

Innovation Partner Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: MASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis. For >20 years, we have been evaluating the efficacy of our clients' drugs using goldstandard experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners. Our expertise – your success.

www.physiogenex.com

Event Partner - Gubra

Expertise Partner Gubra offers expert preclinical research services enabling pharmaceutical and biotech companies to advance their drug development pipeline. Our capabilities in preclinical studies include in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. We employ a combination of unique techniques to profile drug candidates in a wide array of clinically translatable research models.

www.gubra.dk

"Many high-quality talks and exceptional networking opportunities"

Vice President, Cellarity Therapeutics

"The meeting was an excellent conference. It was a highly informative and interactive meeting. The speakers presented cutting edge approaches for novel treatments for obesity and MASH. There was plenty of time for discussions and networking"

CSO, Mitotherapeutix

GET INVOLVED

Ellie Bilko
Senior Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.mashdrugdevelopmentsummit.com/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

Learn from 30+ experts across discovery, preclinical, translational, clinical and regulatory development to expose yourself to new challenges and innovations in liver disease.

Network with 120+ industry attendees dedicated to driving forward the next wave of MASH approvals.

Unearth the latest advancements in MASH drug development and uncover where the field is moving.

Present your novel research at our poster session showcasing novel developments in the field.

Drug Developer Pricing*	Register & Pay By Friday, 14th June	On the Door Price
Conference + Pre-Clinical Workshop Day	$3,097 (save $1,100)	$4,197
Conference + Clinical Workshop Day	$3,097 (save $1,100)	$4,197
Conference Only	$2,299 (save $700)	$2,999

Service Provider Pricing	Register & Pay By Friday, 14th June	On the Door Price
Conference + Pre-Clinical Workshop Day	$3,997 (save $1,100)	$5,097
Conference + Clinical Workshop Day	$3,997 (save $1,100)	$5,097
Conference Only	$2,999 (save $700)	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts**

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5 + Attendees

**Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hilton Boston Logan Airport
One Hotel Drive, Boston, MA 02128, United States
www.hilton.com/en/hotels/boslhhh-hilton-boston-logan-airport/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom